Date: Wednesday, June 21, 2017
Moderator/Analyst: Michael King, Managing Director- Research, Biotechnology, JMP Securities
Panelists: Agenus Inc. (AGEN), Compugen Ltd. (CGEN), Leap Therapeutics, Inc. (LPTX), Pieris Pharmaceuticals, Inc. (PIRS)
Description: Recent clinical success with immune checkpoint blockade has resurrected intense scientific interest in cancer immunotherapy. Key topics slated for discussion include next-generation I/O therapeutics, check point inhibitors, biomarker strategies, the future of combination therapies, and challenges associated with drug cost and coverage.